BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28146043)

  • 21. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDKN2A mutations in melanoma families from Uruguay.
    Larre Borges A; Cuéllar F; Puig-Butillé JA; Scarone M; Delgado L; Badenas C; Milà M; Malvehy J; Barquet V; Núñez J; Laporte M; Fernández G; Levrero P; Martínez-Asuaga M; Puig S
    Br J Dermatol; 2009 Sep; 161(3):536-41. PubMed ID: 19523171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.
    Landi MT; Kanetsky PA; Tsang S; Gold B; Munroe D; Rebbeck T; Swoyer J; Ter-Minassian M; Hedayati M; Grossman L; Goldstein AM; Calista D; Pfeiffer RM
    J Natl Cancer Inst; 2005 Jul; 97(13):998-1007. PubMed ID: 15998953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.
    Pellegrini C; Botta F; Massi D; Martorelli C; Facchetti F; Gandini S; Maisonneuve P; Avril MF; Demenais F; Bressac-de Paillerets B; Hoiom V; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Marrett L; Zanetti R; Dwyer T; Thomas NE; Begg CB; Berwick M; Puig S; Potrony M; Nagore E; Ghiorzo P; Menin C; Manganoni AM; Rodolfo M; Brugnara S; Passoni E; Sekulovic LK; Baldini F; Guida G; Stratigos A; Ozdemir F; Ayala F; Fernandez-de-Misa R; Quaglino P; Ribas G; Romanini A; Migliano E; Stanganelli I; Kanetsky PA; Pizzichetta MA; García-Borrón JC; Nan H; Landi MT; Little J; Newton-Bishop J; Sera F; Fargnoli MC; Raimondi S; ; ;
    Lancet Child Adolesc Health; 2019 May; 3(5):332-342. PubMed ID: 30872112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
    Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
    BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of loss of function MC1R variants in genetic susceptibility of familial melanoma in Spain.
    de Torre C; Garcia-Casado Z; Martínez-Escribano JA; Botella-Estrada R; Bañuls J; Oliver V; Mercader P; Azaña JM; Frias J; Nagore E
    Melanoma Res; 2010 Aug; 20(4):342-8. PubMed ID: 20539244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.
    Goldstein AM; Landi MT; Tsang S; Fraser MC; Munroe DJ; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2208-12. PubMed ID: 16172233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
    Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
    Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma.
    Nikolaou V; Kang X; Stratigos A; Gogas H; Latorre MC; Gabree M; Plaka M; Njauw CN; Kypreou K; Mirmigi I; Stefanaki I; Tsao H
    Br J Dermatol; 2011 Dec; 165(6):1219-22. PubMed ID: 21801156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel and recurrent p14 mutations in Italian familial melanoma.
    Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
    Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
    Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
    J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.
    Pellegrini C; Cardelli L; Ghiorzo P; Pastorino L; Potrony M; García-Casado Z; Elefanti L; Stefanaki I; Mastrangelo M; Necozione S; Aguilera P; Rodríguez-Hernández A; Di Nardo L; Rocco T; Del Regno L; Badenas C; Carrera C; Malvehy J; Requena C; Bañuls J; Stratigos AJ; Peris K; Menin C; Calista D; Nagore E; Puig S; Landi MT; Fargnoli MC
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2498-2508. PubMed ID: 37611275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study.
    Fargnoli MC; Altobelli E; Keller G; Chimenti S; Höfler H; Peris K
    Melanoma Res; 2006 Apr; 16(2):175-82. PubMed ID: 16567973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel CDKN2A mutations in Austrian melanoma patients.
    Burgstaller-Muehlbacher S; Marko M; Müller C; Wendt J; Pehamberger H; Okamoto I
    Melanoma Res; 2015 Oct; 25(5):412-20. PubMed ID: 26225579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
    Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
    Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical histopathological features and CDKN2A/CDK4/MITF mutational status of patients with multiple primary melanomas from Bologna: Italy is a fascinating but complex mosaic.
    Dika E; Patrizi A; Rossi C; Turchetti D; Miccoli S; Ferracin M; Veronesi G; Scarfì F; Lambertini M
    Ital J Dermatol Venerol; 2021 Oct; 156(5):599-605. PubMed ID: 32221274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Increased knowledge on familial melanoma and the underlying genetics].
    Helgadottir H; Nielsen K; Höiom V
    Lakartidningen; 2017 May; 114():. PubMed ID: 28485764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the CDKN2A locus in patients with multiple primary melanomas.
    Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
    J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.